Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: A time-updated propensity analysis

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 6, 2009, Pages 437-447

  Habib, Zeina A ^a   Tzogias, Leonidas ^a   Havstad, Suzannel L ^a   Wells, Karen ^a   Divine, George ^a   Lanfear, David E ^a   Tang, Jeffrey ^a   Krajenta, Richard ^a   Pladevall, Manel ^a   Williams, L Keoki ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Cerebrovascular accident; Congestive heart failure; Coronary heart disease; Mortality; Thiazolidinediones

Indexed keywords

GLITAZONE DERIVATIVE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; ACUTE DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; DRUG COMBINATION; HEART INFARCTION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICS; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 68149170891     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1722     Document Type: Article

References (54)

1. Avandia (Rosiglitazone Maleate) Tablets, FDA Application No. 21-071. 5-25-1999.
2. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286(7): 831-833.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-2471.
4. Saul S, Harris G. Diabetes drug still has risks, doctors warn. (Business/ Financial Desk). The New York Times 2007; June 6; A1.
5. Rosiglitazone: seeking a balanced perspective. Lancet 2007; 369(9576): 1834.
6. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects metaanalysis in rare event studies: the Rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007; 26(24): 4375-4385.
7. Bilous RW. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis? Diabet Med 2007; 24(9): 931-933.
8. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147(8): 578-581.
9. Mulrow CD, Cornell J, Localio AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007; 147(8): 585-587.
10. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189-1195.
11. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005; 48(9): 1726-1735.
12. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357(1): 28-38.
13. McAfee AT, Koro C, Landon J, Ziyadeh N,Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16(7): 711-725.
14. Rosen CJ. The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 2007; 357(9): 844-846.
15. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (4): CD006060.
16. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (3): CD006063.
17. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370(9593): 1129-1136.
18. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomised, controlled trials. N Engl J Med 1997; 337(8): 536-542.
19. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279-1289.
20. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16(10): 1065-1071.
21. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298(22): 2634-2643.
22. Harris GFDA. Issues strictest warning on diabetes drugs.(National Desk)(Food and Drug Administration). The New York Times 2007; June 7; A1.
23. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2): 757-763.
24. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17(19): 2265-2281.
25. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98(3): 253-259.
26. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005; 14(7): 465-476.
27. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27(12): 2800-2805.
28. Vandenbroucke JP, von EE, Altman DG, Gotzsche PC, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147(8): W163-W194.
29. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114(6): 1288-1293.
30. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40(7-8): 1280-1288.
31. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992; 45(6): 613-619.
32. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287(3): 360-372.
33. SAS Institute Inc. SAS/STAT Users Guide. Version 9.1 ed. Cary, NC: SAS Institute Inc.; 2004.
34. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8): 954-959.
35. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339): 1071-1073.
36. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142(3): 157-164.
37. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352(11): 1071-1080.
38. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11): 1092-1102.
39. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142(7): 481-489.
40. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296(13): 1619-1632.
41. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180-1188.
42. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547-1554.
43. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30(10): 2458-2464.
44. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096-1105.
45. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427-2443.
46. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108(23): 2941-2948.
47. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27(1): 256-263.
48. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-1118.
49. Williams LK, Joseph CL, Peterson EL, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007; 120(5): 1153-1159.
50. Sturmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162(3): 279-289.
51. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16(5): 504-512.
52. Lee WY, Capra AM, Jensvold NG, Gurwitz JH, Go AS. Gender and risk of adverse outcomes in heart failure. Am J Cardiol 2004; 94(9): 1147-1152.
53. Pocock SJ, Abdalla M. The hope and the hazards of using compliance data in randomized controlled trials. Stat Med 1998; 17(3): 303-317.
54. Jayaraman S, Rieder MJ, Matsui DM. Compliance assessment in drug trials: has there been improvement in two decades? Can J Clin Pharmacol 2005; 12(3): e251-e253.